Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT)

Charytan, D. M. et al. (2015) Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT). American Journal of Kidney Diseases, 66(3), pp. 429-440. (doi: 10.1053/j.ajkd.2015.02.324) (PMID:25935581)

Abstract

Background The cause of death in patients with chronic kidney disease (CKD) varies with CKD severity, but variation has not been quantified. Study Design Retrospective analysis of prospective randomized clinical trial. Setting and Participants We analyzed 4,038 individuals with anemia and diabetic CKD from TREAT, a randomized trial comparing darbepoetin alfa and placebo. Predictors Baseline estimated glomerular filtration rate (eGFR) and protein-creatinine ratio (PCR). Outcomes Cause of death as adjudicated by a blinded committee.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: McMurray, Professor John
• Authors: Charytan, D. M., Lewis, E. F., Desai, A. S., Weinrauch, L. A., Ivanovich, P., Toto, R. D., Claggett, B., Liu, J., Hartley, L. H., Finn, P., Singh, A. K., Levey, A. S., Pfeffer, M. A., McMurray, J. J.V., and Solomon, S. D.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: American Journal of Kidney Diseases
• Publisher: W.B. Saunders Co.
• ISSN: 0272-6386
• ISSN (Online): 1523-6838